monkeypox

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles before addressing results of Pfizer’s phase 3 RSV vaccine clinical trial for adults under 60, RSV, influenza and SARS-CoV-2 circulation, differences between rural and urban communities dealing with SARS-CoV-2 infections, the latest statistics on influenza and COVID-19 circulation, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, how long COVID affects the brain and associates with an increase in allergic incidents as well as if post SARS-CoV-2 infected patients are unable to exercise or have functional limitations. For more information about this body of work, listen to TWiV 1088.

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles and influenza before addressing Vincent’s comment on measles inclusion in the clinical respiratory PCR panel, the latest statistics on influenza and COVID-19 circulation, if inflammatory cytokines and anti-viral antibody function synergistically, if administration of peptide agonists of the glucagon-like or sodium-glucose pump can reduce disease severity, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines for SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year longitudinal study on long COVID. For more information about this body of work, listen to TWiV 1088.

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles influenza and SARS-CoV-2, before discussing the development of new monoclonal antibody therapy, if vaccines and antivial drugs can used effectively together. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if one can predict the loss infectivity of healthcare workers with mild COVID-19 disease and the dynamics of household transmission of the virus in children.

In his weekly clinical update, Dr. Griffin deep dives into recent domestic and global measles and mpox outbreaks, before reviewing recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2, discussing revised guidelines for how to treat respiratory viral infection guidelines by the CDC, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, how much oxygen is necessary for effective treatment of severe disease, how COVID-19 effects the cardiovascular system of children and adolescents with long COVID and how iron metabolism may be altered during long COVID.

In his weekly clinical update, Dr. Griffin highlights measles outbreaks throughout the continental US, reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing if vaccination protected children from the development of long COVID or cardiovascular diseases associated with virus infection, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, how COVID-19 effects the autonomic nervous system, and if nirmatrelvir-ritonavir protects against adverse cardiovascular effects following SARS-CoV-2 infection.

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing revised guidelines for how to treat respiratory viral infection guidelines by the CDC, effectiveness of the new SARS-CoV-2 vaccines and the combination of vaccination and antiviral therapy against the development of disease, continues to dispel the myth of viral rebound, how to pay for paxlovid, the lack of evidence supporting ivermectin as an antiviral drug, when to use steroids and the benefits of convalescent plasma, how COVID-19 affects cognitive function and the effect of long COVID and how healthcare works have difficulty making the proper diagnosis for long COVID even using a questionnaire.

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing new vaccine guidelines released by the advisory committee on immunization practices, and reviews the CDC guidelines for quarantine/ isolation following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, the role of IFN- in long COVID, if the brain-blood-barrier is compromised in long COVID, meaning of persistent community SARS-CoV-2 RNA findings, and the effects of hyperbaric oxygen on post COVID neurocognition

In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK’s RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the CDC or WHO definition of long COVID is beneficial or the use of directed questions, baselines test and listening to the patient tell their story are beneficial in making a long COVID diagnosis.

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market and why people conceal their infectious diseases before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if susceptibility and disease severity are inheritable traits, if vaccination during pregnancy protects neonates or leads to adverse effects, the effectiveness of a monovalent XBB.1.5 against disease resulting from infection with Omicron variants, whether vaccination in the same or opposite arms effect antibody protection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how SARS-CoV-2 infection may alter one’s sleep patterns, what the health and economic burdens of mild disease are, and if there are predictors for recovery from fatigue and cognitive deficits following SARS-CoV-2 infection.